A renal cell carcinoma is a form of cancer that affects patients’ kidneys. They are two vital organs that resemble the shape of a bean and are about the size of a human fist. They are found on either side of the patients’ spine just behind the abdomen. The function of the kidneys is to get rid of waste products and surplus fluids from their bodies. In the above condition, the malignant cancerous cells first develop and rapidly reproduce in the patients’ kidneys’ tubules. Within a short time, they spread and infect the other parts of their bodies
Paolo Boffetta– What targeted therapy drugs are available for treating renal cell carcinoma?
Dr. Paolo Boffetta is a well-known cancer research specialist from Italy who currently stays in America. His area of expertise is in molecular, cardiovascular, genetic, and diabetes epidemiology. He even has a wealth of knowledge of cancer prevention and treatment methods. He has the honor of working in the top international cancer research institutions throughout his illustrious career. These include the German Cancer Research Center, American Cancer Society, Columbia University, International Agency for Research on Cancer, and American Health Foundation. He is presently a Director at the Institute for Translational Epidemiology.
Read more: An update on CVS stock on covidpandamic
As highlighted by Paolo Boffetta doctors find it challenging to treat patients whom they suspect to be suffering from renal cell carcinoma. This is because the symptoms of this form of cancer are not easily visible during their screening. However, they rapidly develop to include traces of blood in the patients’ urine, fever, tiredness, sudden weight loss, and hypertension. In some cases, the patients even develop a lump in their abdomen and suffer from anemia. This is when their doctors have to refer them to qualified cancer specialists who conduct a thorough diagnosis. Only then do these medical experts prescribe following targeted therapy drugs to treat and cure them:
- Sunitinib which attacks and blocks all of the growth-enhancing proteins present in the malignant cancer cells,
- Sorafenib (Nexavar) works in the same manner as Sunitinib by targeting the enzymes responsible for cancerous cells’ growth.
- Pazopanib (Votrient) blocks numerous enzymes known as tyrosine kinases, which act as catalysts in cancerous cells’ development.
- Lenvatinib (Lenvima) blocks the blood supply to cancerous tumor cells and attacks the proteins responsible for their division, and
- Temsirolimus (Torisel) is an intravenous (IV) infusion drug that blocks mTOR proteins to prevent cancer cell growth and division.
In the opinion of Paolo Boffetta renal cell carcinoma is a common type of cancer affecting the patients’ kidneys. Initially, doctors might not find any visible symptoms or signs of this disease when screening their patients. However, they might later develop to include traces of blood in the urine, fever, tiredness, sudden weight loss, and hypertension. Some patients might even lump their abdominal region. Fortunately, this form of cancer is curable if present in the early stages. To achieve this goal, doctors prescribe and administer certain targeted therapy drugs to their patients. These include Sunitinib, Sorafenib, Pazopanib, Lenvatinib, and Temsirolimus.